Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03539536 · ClinicalTrials.gov registry record · Phase 2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by AbbVie.
- Active
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT03539536 is a Phase 2 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 270 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT03539536, a Phase 2 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).
Conditions Studied
Interventions
- DRUG Telisotuzumab vedotin
Study Locations (20)
Illinois
- Northwestern University Feinberg School of Medicine /ID# 203239 - Chicago
- The University of Chicago Medical Center /ID# 203216 - Chicago
- Duplicate_NorthShore University HealthSystem /ID# 215583 - Evanston
- Ingalls Memorial Hosp /ID# 203228 - Harvey
- Joliet Oncology-Hematology Associates, LTD /ID# 203238 - Joliet
California
- University of California, Los Angeles /ID# 203219 - Los Angeles
- LA Hematology-Oncology Med Group /ID# 203338 - Orange
- Sutter Medical Center Sacramen /ID# 203299 - Sacramento
- Icri /Id# 227835 - Whittier
Florida
- Advanced Cancer Treatment Center /ID# 239565 - Brooksville
- AdventHealth Celebration /ID# 215649 - Celebration
- Duplicate_Mayo Clinic /ID# 218488 - Jacksonville
- Duplicate_AdventHealth Cancer Institute - Orlando /ID# 239960 - Orlando
Colorado
- Univ of Colorado Cancer Center /ID# 203212 - Aurora
- Duplicate_Rocky Mountain Cancer Centers - Lone Tree /ID# 215789 - Lone Tree
Alabama
- University of South Alabama /ID# 212939 - Mobile
Arizona
- Mayo Clinic Arizona /ID# 218550 - Phoenix
Arkansas
- Highlands Oncology Group, PA /ID# 215600 - Springdale
Hawaii
- Straub Clinic and Hospital /ID# 217905 - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03539536
The ClinicalTrials.gov registry entry for NCT03539536 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (59% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Telisotuzumab vedotin is the first listed.
NCT03539536 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Illinois, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03539536 about?
NCT03539536 is a clinical study titled "Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer". This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected...
What is the current status of trial NCT03539536?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2018-10-10. Estimated completion is 2026-08.
What conditions does trial NCT03539536 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03539536?
The interventions under investigation include: Telisotuzumab vedotin (DRUG).
Who is sponsoring clinical trial NCT03539536?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03539536 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.